Clinical trials: Atopic Eczema
Atopic Dermatitis Eczema
Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema
Up to 30 participants with mild to moderate atopic dermatitis/eczema will be enrolled to apply study Investigational Product for 4 weeks.
- Trial name
- NCT05918237
- Testing
- Arctiva
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ClinOhio Research Services, LLC
Atopic Dermatitis
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
- Trial name
- ATLAS (NCT03533751)
- Testing
- Etokimab
- Where
- 81 sites in United States, Canada and 4 more
- Volunteers
- 302 people
- Sponsor
- AnaptysBio, Inc.
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- ADvocate2 (NCT04178967)
- Testing
- Lebrikizumab
- Where
- 89 sites in United States, Bulgaria and 6 more
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic, Dermatitis Eczema
A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis
This is a dose escalation study to test the safety, tolerability and preliminary efficacy of ASN002 in people with moderate to severe atopic dermatitis (AD).
- Conditions
- Dermatitis, Atopic, Dermatitis Eczema, Dermatitis, Eczematous
- Trial name
- NCT03139981
- Testing
- ASN002
- Where
- 10 sites in United States, Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Asana BioSciences
Dermatitis, Atopic, Pruritus
Study to Evaluate ASN008 Topical Gel (TG)
This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects
- Conditions
- Dermatitis, Atopic, Pruritus, Dermatitis Eczema
- Trial name
- NCT03798561
- Testing
- ASN008 TG
- Where
- 5 sites in United States, Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Asana BioSciences
Atopic Diathesis, Eczema-prone Skin
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis
The aim of this study is to compare the efficacy and tolerability and of a cosmetic product to one that is already available on the market (benchmark product).
- Trial name
- NCT05807113
- Testing
- Atopi intensive care BNO 3731, Benchmark product
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Atopic Dermatitis, Eczema-Prone Skin
Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema
The aim of this exploratory study is to investigate the short- and long-term efficacy and tolerability of a cosmetic product combination consisting of a body lotion and an intensive care product in subjects with atopic eczema…
- Trial name
- AtoCare-OS (NCT05790083)
- Testing
- Body Lotion and Intensive Care
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Atopic Diathesis, Eczema-Prone Skin
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 4 Weeks of Use on Subjects With Atopic Dermatitis
The aim of this study is to compare the efficacy and tolerability of a cosmetic product to one that is already available on the market (benchmark product).
- Trial name
- NCT05786976
- Testing
- Lotion BNO 3732, Body Lotion Benchmark product
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Atopic Dermatitis
CLINICAL EFFICACY OF EMOLLIENTS IN ATOPIC DERMATITIS PATIENTS
his was a monocentric, intra-individual study, that was performed in at least 45 valid cases (50% children ≥3 YO; 50% adults). Study duration was 168 days with five (5) visits (D0, D14, D28, D84 and D168) to the research center.
- Trial name
- NCT05783453
- Testing
- Cosmetic study
- Where
- Brazil
- Volunteers
- 63 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis
This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12 years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.
- Trial name
- NCT05614817
- Testing
- CBP-201
- Sponsor
- Connect Biopharm LLC
Atopic Dermatitis
A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis
This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.
- Trial name
- NCT04040192
- Testing
- Crisaborole 2%, Vehicle
- Where
- 44 sites in United States, Australia and 4 more
- Volunteers
- 620 people
- Sponsor
- Pfizer
Atopic Dermatitis, Atopic Dermatitis Eczema
The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (14 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
- Trial name
- NCT05719649
- Testing
- Lactic acid bacteria NTU 101
- Volunteers
- 72 people
- Sponsor
- SunWay Biotech Co., LTD.
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis Eczema
Metal Panel Allergen Patch Test Study
Metal allergen patch test study.
- Trial name
- NCT04500834
- Testing
- Metal Panel T.R.U.E. Test
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Allerderm
Atopic Dermatitis
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
B7451037 is a randomized, double-blind, placebo-controlled, parallel-group, Phase 2a study to investigate the mechanism of action of PF-04965842 by correlating efficacy outcomes with changes from baseline in key skin and blood…
- Trial name
- JADE MOA (NCT03915496)
- Testing
- PF-04965842 200 mg, PF-04965842 100 mg
- Where
- 11 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Pfizer
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- NCT04146363
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
The purpose of this study is to evaluate the efficacy (assessed by clinical evaluation of eczema/atopic lesion severity [atopic dermatitis severity index {ADSI} scoring] and perceived benefits in itch [visual analog score {VAS}…
- Trial name
- NCT05226143
- Testing
- Gel Cream
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
The Effect of Isosorbide Diesters Based Moisturizer on Skin Health
The overall objective of this study is to assess how a natural ingredient, isosorbide diesters (IDEAS), works in association with colloidal oatmeal for eczema.
- Trial name
- NCT04831892
- Testing
- Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal, Moisturizer containing Colloidal Oatmeal only
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Integrative Skin Science and Research
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- BREEZE-AD6 (NCT03559270)
- Testing
- Baricitinib
- Where
- 74 sites in United States, Canada and 1 more
- Volunteers
- 374 people
- Sponsor
- Eli Lilly and Company